Highlights:

ResMed operates within the medical devices and healthcare equipment sector with global distribution capabilities

Key focus remains on respiratory support devices, sleep treatment technology, and digital health tools

ResMed is listed on the S&P 200 index, reflecting its stature in Australia’s top market entities

Healthcare Equipment Sector and S&P 200 Index Alignment
ResMed (ASX:RMD) is positioned within the healthcare equipment sector, primarily focused on respiratory and sleep-related medical technologies. As a constituent of the S&P 200, the company is included among Australia's top-listed companies by market capitalisation. The S&P 200 index aggregates high-performing stocks across multiple sectors, offering a benchmark of equity strength across Australia’s public market.

ResMed’s operations extend across North America, Europe, and the Asia-Pacific region. Its primary business areas include devices for the treatment of sleep apnoea, cloud-connected respiratory care solutions, and out-of-hospital software platforms. The company’s global footprint and technological approach place it among major healthcare technology providers in the sector.

Respiratory Devices and Treatment Technology
ResMed develops and markets devices that treat chronic respiratory conditions. These include positive airway pressure (PAP) machines, ventilators, and related accessories. Its devices are tailored for sleep apnoea treatment and chronic obstructive pulmonary disease (COPD), two of the most common long-term respiratory challenges.

Its product range integrates remote monitoring capabilities through connected platforms, allowing clinicians to access patient data and adjust treatment in real time. Devices are equipped with compact designs, advanced airflow mechanisms, and user-friendly interfaces that serve patients in clinical and homecare environments. The integration of hardware and digital support tools underpins the company’s consistent innovation in this field.

Digital Health and Software-as-a-Service Solutions
ResMed’s digital health strategy supports both patients and care providers with cloud-based platforms and applications. Its software solutions help manage out-of-hospital care coordination across home medical equipment providers, skilled nursing facilities, and long-term care services.

The company’s SaaS segment includes tools for patient engagement, therapy adherence, and operational workflow support. These platforms are designed to improve treatment efficacy while streamlining healthcare administration. Integration of artificial intelligence and machine learning tools enhances predictive tracking of therapy compliance and respiratory performance.

Research and Product Development Expansion
ResMed maintains ongoing development of new treatment platforms, accessories, and software updates. Its research hubs across Sydney, San Diego, and Singapore focus on improving device ergonomics, expanding connectivity functions, and refining sleep and respiratory care diagnostics.

Collaborations with health systems and academic research centres enable ResMed to incorporate the latest clinical findings into product development. These include studies on respiratory disease patterns, data-driven patient support models, and remote healthcare delivery mechanisms. The ongoing focus on improving long-term health outcomes through device innovation remains central to the company's business structure.

Global Distribution and Market Reach
ResMed operates through a diversified network of distributors, healthcare partners, and service providers in more than a hundred countries. The company’s scale is supported by regional manufacturing sites, centralised logistics operations, and local partnerships for regulatory navigation.

Through its presence in the S&P 200 index, ResMed reflects a key representation of the Australian healthcare technology sector. The index places it among established firms that contribute to national and international health services. While headquartered in Australia, its financial performance and product distribution are largely driven by operations in the United States and Europe, linking it to global demand for respiratory therapy solutions.